News and Press Releases about the Novocure Optune™ System

• 01/06/16 Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System
  
  
• Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients Optune can now be used even if you have a non programmable shunt!
  
  
• FDA Approves Optune for Newly Diagnosed Glioblastoma Patients. Risk of death reduced by 37%!
  
  
• Novocure to Present Fifteen Abstracts Describing Latest Aspects of NovoTTF Therapy at the 4thQuadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)
  
  
• Centers for Medicare and Medicaid Services (CMS) Has Established Permanent Billing Codes for the NovoTTF-100A System
  
  
•      NOVOCURE PRESENTS RESULTS FROM BREAST CANCER PILOT STUDY (Mentions GBM also)
  
  
•     FDA Approves the NovoTTF-100A System for the Treatment of Patients with Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
  
  
•     Novel Electric Helmet Slows Brain Tumors Without Chemotherapy Side Effects
  
  
•      NOVOCURE REPORTS DATA SHOWING TTF THERAPY IN COMBINATION WITH CHEMOTHERAPY HAS THE POTENTIAL TO INCREASE OVERALL SURVIVAL FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (Editor`s Note: Although not related to brain tumors, this shows that the Novo TTF device has a strong effect on cancer.
  
  
•      Novocure Establishes Initial Clinical Centers of Excellence for Treatment of Recurrent Glioblastoma Multiforme with Tumor Treating Fields (TTFields) Therapy
  
  
•      SUCCESSFUL PHASE III CLINICAL TRIAL RESULTS REPORTED FOR NOVOCURE'S NOVEL MEDICAL DEVICE FOR TREATMENT OF RECURRENT GLIOBLASTOMA
  
  
•      STUDIES SHOW NOVEL DEVICE MAY ENHANCE CHEMOTHERAPY TREATMENT IN BRAIN TUMORS
  
  
•      NovoCure, Ltd., Announces the Closing of a Financing Round Including New Investors Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures
  
  
•      Updated Survival Data from Study Comparing TTF (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
  
  
•      Fighting brain cancer with electricity
  
  
•      Professor Zvi Ram Presents Phase III Recurrent Glioblastoma Survival and Quality of Life Data from the First Pivotal Study of the NovoTTF-100A at the 15th Annual Society for Neuro-Oncology (SNO) Scientific Meeting
  
  
•      NOVEL DEVICE SHOWN TO BENEFIT SURVIVAL FOR BRAIN CANCER PATIENTS WHEN COMBINED WITH CHEMOTHERAPY
  
  
•     Innovative device to treat brain cancer shows promise in early studies
  
  
•     FDA votes to approve Novocure Device
  
  
•     Activism Alert: Please sign petition to help get the Novocure Novo-TTF-100a device approved for recurrent glioblastoma!
  
  
•      Experimental Device Used To Treat Deadly Brain Cancer
  
  
•      Activism Alert Update: Please sign petition to help get the Novocure Novo-TTF-100a device approved for recurrent glioblastoma!
  
  
•      Electric Fields Kill Tumors A promising device uses electric fields to destroy cancer cells in the brain.
  
  
•     FDA clears first-of-a-kind device for brain cancer (Mentions Musella Foundation!)
  
  
•      Device for Glioblastoma May Offer Advantage Over Chemo
  
  
•      IBTA E News October 2010
  
  
•      Electrifying new brain cancer weapon
  
  
•      Patient Receives First Prescription for FDA-Approved Brain Tumor Treatment
  
  
•     Letter writing campaign now closed!
  
  
•     Electrical Device for Cancer Treatment Polarizes Audiences
  
  
•      New Brain Tumor Videos Added to virtualtrials.org
  
  
•      IBTA E News April 2011
  
  
•      Brain Cancer Zapper
  
  
•      International Brain Tumor Alliance Newsletter!
  
  
•      IBTA E News November-December 2011
  
  
•      Device with AC current is comparable to chemo for recurrent glioblastoma
  
  
•      ET-03. THE EFFICACY OF TEMOZOLOMIDE IN VITRO AND IN PATIENTS WITH NEWLY DIAGNOSED GBM IS ENHANCED BY ADJUVANT EXPOSURE TO ALTERNATING ELECTRIC FIELDS (TTFIELDS)
  
  
•      FDA panel: Benefits outweigh risks of non-invasive therapy for glioblastoma
  
  
•      IBTA E NEWS AUGUST-SEPTEMBER 2011
  
  
•     FDA Advisory Panel Endorses New GBM Treatment
  
  
•      IBTA E News March 2011
  
  
•      IBTA E News February 2011
  
  
•      IBTA E-News May 2010
  
  
•      IBTA E-News March 2010
  
  
•      Heroes of Hope Race and Kids Fun Run to Benefit Brain Tumor Research
  
  
•      BRAIN TUMOUR SUPPORTERS WALK THE EQUIVALENT OF MORE THAN TWICE AROUND THE WORLD
  
  
•     200,000 PEOPLE WORLDWIDE AFFECTED EACH YEAR BY HIGHLY MALIGNANT BRAIN TUMOURS
  
  
•      University Evaluates New Device To Treat Brain Tumors
  
  

---

Click on the links below for more information on Optune™.